Quick Answer
Roivant Sciences Ltd. reported Operating Income Loss of -$1.00 billion for the year ending 2025.
- Roivant Sciences Ltd. showed a decrease of -122.3% in Operating Income Loss from 2024 to 2025.
- This data is from Roivant Sciences Ltd.'s annual report (Form 10-K), filed with the SEC on May 29, 2025.
- XBRL data for this metric is available from 2021 to 2025 (5 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2020: -$114.45 million | Q3 2020: -$156.54 million | Q4 2020: -$259.07 million | Q2 2021: -$154.39 million | Q3 2021: -$684.43 million | Q4 2021: -$246.02 million | Q2 2022: -$282.31 million | Q3 2022: -$280.77 million | Q4 2022: -$378.08 million | Q2 2023: -$276.41 million | Q3 2023: -$213.89 million | Q4 2023: $5.13 billion | Q2 2024: -$102.24 million | Q3 2024: -$341.71 million | Q4 2024: -$274.38 million | Q2 2025: -$284.92 million | Q3 2025: -$306.23 million | Q4 2025: -$339.15 million.
- Over the full 5 years of available data (2021 to 2025), Roivant Sciences Ltd.'s Operating Income Loss has grown by 6.3%.
- Historical annual values: Fiscal year 2025: -$1.00 billion | Fiscal year 2024: $4.50 billion | Fiscal year 2023: -$906.76 million | Fiscal year 2022: -$1.35 billion | Fiscal year 2021: -$1.07 billion.
- Data sourced from SEC EDGAR public filings as of August 10, 2026.
Last verified: